(c) 2024 PillSync.com

Carisoprodol 350 MG Oral Tablet

1. INDICATIONS AND USAGE Carisoprodol tablets USP is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol tablets USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [ see Dosage and Administration (2) ]. Carisoprodol tablets USP is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults ( 1 ) Limitations of Use : Should only be used for acute treatment periods up to two or three weeks ( 1 )

Jubilant Cadista Pharmaceuticals Inc.


4 years ago ROUND WHITE OP 35 Carisoprodol 350 MG Oral Tablet

ROUND WHITE OP 35

16 HOW SUPPLIED/STORAGE AND HANDLING Carisoprodol tablets USP, 350 mg : white to off-white circular biconvex tablets, debossed with logo-mark "OP" and product number "35" on one side and no mark on the other side; available in bottles of 100 (NDC 59746-705-01), bottles of 1,000 (NDC 59746-705-10), and bottles of 500 (NDC 59746-705-05). Storage: Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].


More pills like ROUND OP 35

Related Pills

carisoprodol 350 mg

Orient Pharma Co., Ltd.

carisoprodol tablet

Orient Pharma Co., Ltd.

carisoprodol tablet

Orient Pharma Co., Ltd.

carisoprodol tablet

orient pharma co., ltd.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site